Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06910787 · ClinicalTrials.gov registry record · NA

Outpatient VR (Virtual Reality)-Brain-gut Behavioral Therapies (BGBT) in Inflammatory Bowel Disease (IBD)

A NA study of Inflammatory Bowel Diseases, sponsored by University of Michigan.

Recruiting
Registry status
NA
Development phase
40
Enrollment target
1
Study location

NCT06910787: Recruiting NA study of Inflammatory Bowel Diseases, sponsored by University of Michigan.

NCT06910787 is a NA study of Inflammatory Bowel Diseases that is actively recruiting participants, run by University of Michigan. The registered enrollment target is 40 participants, below the 42,261-participant average among 48 other Inflammatory Bowel Diseases trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06910787, a NA study of Inflammatory Bowel Diseases, is actively recruiting participants, sponsored by University of Michigan.

RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

This research study is being done to learn if a virtual reality (VR)-directed BGBT program is feasible and acceptable for patients to enhance pain treatment for patients with IBD. The study hypothesis include: * the study will achieve greater than 75% program completion and 75% study assessment completion * patients with IBD will find VR-directed BGBT acceptable as an outpatient pain treatment * outpatient VR-directed BGBT in IBD arm participants will report a greater reduction in pain scores, symptom burden, stress, depression, anxiety, and pain-related interference and an improvement in health-related quality of life * will have lower opioid requirements and healthcare utilization at 4-weeks follow-up compared to the E-TAU arm

Primary Outcome

The study team hypothesizes the study will achieve greater than 75% program completion and 75% study assessment completion.

Interventions

  • DEVICE VR-directed BGBT
  • OTHER E-TAU

Study Locations (1)

Michigan

  • University of Michigan - Ann Arbor

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-04-29
Est. Completion 2027-10
Phase NA
University of Michigan

1,327 total trials

What NCT06910787 shows while recruiting

NCT06910787 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 42,261-participant average among 48 other Inflammatory Bowel Diseases trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Inflammatory Bowel Diseases appearing as the primary indexed condition, and to 2 interventions - of which VR-directed BGBT is the first listed.

NCT06910787 reports a single indexed study location in Michigan.

Frequently Asked Questions

What is clinical trial NCT06910787 about?

NCT06910787 is a clinical study titled "Outpatient VR (Virtual Reality)-Brain-gut Behavioral Therapies (BGBT) in Inflammatory Bowel Disease (IBD)". This research study is being done to learn if a virtual reality (VR)-directed BGBT program is feasible and acceptable for patients to enhance pain treatment for patients with IBD. The study hypothesis include: * the study will achieve greater than 75% program completion and 75% study assessment co...

What is the current status of trial NCT06910787?

This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2025-04-29. Estimated completion is 2027-10.

What conditions does trial NCT06910787 study?

This clinical trial studies the following conditions: Inflammatory Bowel Diseases.

What interventions are being tested in trial NCT06910787?

The interventions under investigation include: VR-directed BGBT (DEVICE), E-TAU (OTHER).

Who is sponsoring clinical trial NCT06910787?

This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06910787 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Inflammatory Bowel Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06910787's enrollment target sits among peer trials

40 39th of 48 higher than 9 of 48 other Inflammatory Bowel Diseases trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Inflammatory Bowel Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06910787, the US trial registry maintained by the National Library of Medicine. NCT06910787 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.